Highest-materiality recent filing
GSK terminates collaboration with Alector after Phase 3/2 failures; loan repaid
GSK provided notice terminating the collaboration agreement for latozinemab and nivisnebart, effective Jan 2, 2027.
Alector annual meeting elects three directors, ratifies auditor, passes say-on-pay
Class II directors Elizabeth Garofalo, Errol De Souza, Kristine Yaffe elected with broker non-votes of 36.7M each.
Alector Q1 net loss $22.9M ($0.21/sh); discontinues Phase 2 nivisnebart trial after futility
Net loss of $22.9M ($0.21/sh) vs $40.5M ($0.41) in Q1 2025; revenue $1.0M down from $3.7M.
Alector enters $125M ATM equity facility with TD Cowen
May sell up to $125M of common stock from time to time through TD Cowen in at-the-market offerings.
Alector Q4 net loss $37.3M ($0.34/share); revenue down 89% YoY; cash $256M
Q4 2025 net loss $37.3M vs $2.1M in Q4 2024; full-year net loss $142.9M ($1.39/share).
Alector appoints Neil Berkley as CFO; he continues as CBO, effective Dec 10, 2025
Neil Berkley named permanent CFO; had served as Interim CFO since June 2025.
Alector Q3 net loss $34.7M; cash $291.1M; selects lead candidates AL137, AL050; RIF 47%
Net loss $34.7M ($0.34/sh) vs $42.2M ($0.43) in Q3 2024; revenue $3.3M, down from $15.3M.
Alector's Phase 3 latozinemab trial fails; workforce cut 49%, R&D head resigns
Phase 3 INFRONT-3 trial of latozinemab in FTD-GRN missed clinical co-primary endpoint; biomarker endpoint met but no treatment effects seen.
Alector Q2 net loss $30.5M; cash $307.3M; Phase 3 latozinemab data mid-Q4
Net loss $30.5M ($0.30/sh) vs $38.7M ($0.40/sh) in Q2 2024; revenue $7.9M down from $15.1M.
Alector CFO Marc Grasso resigns; Neil Berkley named interim CFO
CFO Marc Grasso resigns effective June 20; Neil Berkley, CBO, becomes interim CFO while continuing as CBO.
Alector Q1 net loss $40.5M ($0.41/sh); INFRONT-3 data on track for Q4 2025
Net loss of $40.5M ($0.41/sh) vs $36.1M ($0.38/sh) in Q1 2024; collaboration revenue $3.7M (down from $15.9M).
Alector CMO Gary Romano resigns effective April 25, 2025
Dr. Gary Romano notified resignation from CMO role on March 25, 2025.
Alector cuts workforce by ~13% (25 employees); expects $2.4M restructuring charges
Reduction in force impacting ~25 employees, or ~13% of workforce, to align resources with strategic priorities.
Alector Q4 net loss narrows to $2.1M; latozinemab Phase 3 data expected Q4 2025
Q4 2024 net loss $2.1M ($0.02 loss per share) vs $41.4M loss ($0.49 loss) in Q4 2023, revenue $54.2M vs $15.2M.
AbbVie terminates TREM2 program and collaboration with Alector after Phase 2 miss
INVOKE-2 Phase 2 trial of AL002 in early Alzheimer's disease did not meet primary endpoint (announced Nov 25, 2024).
Alector AL002 Phase 2 fails primary endpoint; cuts workforce 17%
AL002 did not slow Alzheimer's progression on CDR-SB; no benefit on secondary endpoints or biomarkers.
Alector secures up to $50M credit facility from Hercules Capital; draws $10M initially
Initial $10M drawn at closing; $15M available upon request through June 2026; $25M at lender's discretion.
Alector reports Q3 net loss $42.2M ($0.43/share); cash $457.2M funds through 2026
Cash, cash equivalents, investments $457.2M as of Sep 30, 2024, sufficient to fund operations through 2026.
Alector Q2 net loss $38.7M vs $1.4M income YoY; cash $503M, INVOKE-2 data on track for Q4 2024
Net loss of $38.7M ($0.40 per share) compared to net income of $1.4M in Q2 2023.
Louis J. Lavigne, Jr. elected with 72,044,245 votes for, 884,614 withheld.
Alector Q1 net loss $36.1M ($0.38/share); cash runway through 2026
Q1 net loss $36.1M ($0.38/share) vs $45.9M ($0.55) in Q1 2023.
Alector announces director resignation and appointment of two new board members
Terry McGuire resigns from Board and all committees effective March 20, 2024; personal reasons, no disagreement.
Alector reports Q4 net loss $41.4M; cash runway extended to 2026 after $75M equity offering
Q4 net loss $41.4M ($0.49/sh) vs $52.4M ($0.63) YoY; FY net loss $130.4M ($1.56) vs $133.3M ($1.62).
Alector prices $75M public offering of ~10.9M shares at $6.57 per share
Priced 10.9M shares at $6.57; gross proceeds ~$75M before discounts and expenses.
Alector reports preliminary cash of ~$549M as of Dec 31, 2023; runway into H2 2026
Preliminary cash, cash equivalents, and short-term investments of ~$549 million as of December 31, 2023.
Alector Q3 net loss $44.5M ($0.53/share); cash runway through 2025
Collaboration revenue $9.1M, down from $14.9M YoY; net loss $44.5M vs $46.1M in Q3 2022.
Alector signs $125M ATM equity sales agreement with TD Cowen
Up to $125 million of common stock may be sold from time to time in at-the-market transactions.
Alector reports Q2 net income $1.4M, cash $630M; updates clinical trial timelines
Q2 2023 revenue $56.2M (down 30% YoY); net income $0.02 EPS vs $0.12 EPS in Q2 2022.
Alector amends bylaws, elects directors, ratifies auditor at 2023 annual meeting
Bylaws amended effective June 15, 2023, to update stockholder nomination procedures and comply with Delaware law and universal proxy rules.
Revenue $16.5M (down $8M YoY); net loss $45.9M ($0.55/share) vs $44.6M ($0.54/share) in Q1 2022.
Director and Chairperson Tillman Gerngross to resign from Alector's board in June 2023
Gerngross resigns as Board Chairperson effective June 13, 2023, and as director effective June 15, 2023.
Alector cuts workforce by 11% (30 employees) to focus on late-stage immuno-neurology programs
Workforce reduction of ~11% (30 employees) effective March 29, 2023.
Alector reports ~1% cash at Silicon Valley Bank; no material impact expected
As of March 10, 2023, ~1% of total cash, cash equivalents, and marketable securities held at SVB.
Alector reports Q4 2022 net loss of $52.4M; cash runway through 2025
Net loss Q4 2022: $52.4M ($0.63/share) vs $55.6M ($0.68) in Q4 2021; full-year net loss $133.3M ($1.62) vs $36.3M ($0.45).
Alector Q3 2022 net loss $46.1M, cash $758.3M, pipeline advances
Net loss of $46.1M ($0.56 loss per share); prior-year net income $126.6M ($1.56 EPS).
Alector Chief Development Officer Robert King resigns effective Oct 28, 2022
Robert King, Ph.D., Chief Development Officer, resigned effective October 28, 2022.
Alector increases inducement equity plan shares to 3.3M for new employee hiring
Board approved amendment raising shares available under 2022 Inducement Plan from 1,630,000 to 3,300,000.
Alector Q2 net income $9.9M, cash $808.9M; AL044 IND submitted
Net income $9.9M ($0.12/share) vs net loss $55.1M ($0.69) in Q2 2021; collaboration revenue rose to $79.9M from $6.6M.
AbbVie terminates Alector's AL003/CD33 Alzheimer's collaboration
AbbVie provided written notice on June 30, 2022 terminating the CD33 (AL003) program.
Alector annual meeting results: all director nominees elected, auditor ratified, say-on-pay approved
Class I directors Rosenthal, Hammond, Wehner elected with ~94% votes for each against votes withheld.
Collaboration revenue $24.5M (vs $4.1M YoY) from GSK agreement; net loss $44.6M ($0.54/share) improved from $52.2M loss.
Alector appoints Gary Romano, M.D., Ph.D., as CMO effective May 23, 2022
Appointed Gary Romano, M.D., Ph.D., as Chief Medical Officer, effective May 23, 2022.
Alector Q4 2021 net loss $55.6M; cash $735M plus $200M from GSK; pipeline advancing
Net loss Q4 2021 $55.6M ($0.68/share) vs $52.2M ($0.66) in Q4 2020; full-year net loss $36.3M ($0.45) vs $190.2M ($2.45).
Alector appoints Marc Grasso, M.D. as CFO; base salary $480K, stock option 450K shares
Marc Grasso appointed CFO effective Feb 7, 2022; succeeds interim CFO Linda Rubinstein.
Alector adopts 2022 Inducement Equity Plan, reserves 1.63M shares for new hires
Board adopted 2022 Inducement Plan effective Jan 1, 2022, reserving 1,630,000 shares of common stock.
Last day of employment December 31, 2021; separation agreement includes $375,000 severance payment and $337,500 bonus.
Alector appoints Sara Kenkare-Mitra as President and Head of R&D
Dr. Kenkare-Mitra joins from Genentech, most recently SVP of Development Sciences.
Collaboration revenue $182.4M (vs $5.9M YoY) driven by $500M upfront from GSK deal.
Alector appoints Elizabeth Garofalo, M.D. to Board of Directors
Dr. Garofalo appointed as Class II director with term expiring at 2023 annual meeting; effective Sept. 23, 2021.
Linda Rubinstein, partner at FLG Partners, appointed interim CFO, Principal Financial Officer and Principal Accounting Officer effective Sept 8, 2021.
Effective upon Dr. Grasso’s resignation, Neil Berkley will be Chief Business Officer and Interim Chief Financial Officer, serving as the principal financial officer of Alector
On June 9, 2025, Dr. Marc Grasso gave notice of his decision to resign from his position as Chief Financial Officer of Alector, Inc. (“Alector”) in order to pursue other opportunities.
and Grace Wong-Sarad will be the Vice President, Accounting, serving as the principal accounting officer of Alector.
On March 25, 2025, Dr. Gary Romano gave notice of his decision to resign from his position as Chief Medical Officer of Alector, Inc. (the “Company”) in order to pursue other opportunities.
On March 19, 2024 (the “Appointment Date”), each of Errol De Souza, Ph.D. and Mark Altmeyer was appointed to the Board.
On March 15, 2024, Terry McGuire informed Alector, Inc. (the “Company”) of his resignation as a member of the Board of Directors (the “Board”) and all committees and subcommittees thereof, effective close of business March 20, 2024.
On March 19, 2024 (the “Appointment Date”), each of Errol De Souza, Ph.D. and Mark Altmeyer was appointed to the Board.
On April 25, 2023, Tillman Gerngross, Ph.D. informed Alector, Inc. (the “Company”) of his resignation as Chairperson of the Company’s board of directors (the “Board”), effective June 13, 2023, and his resignation as a director of the Board, effective June 15, 2023.
On April 25, 2023, Tillman Gerngross, Ph.D. informed Alector, Inc. (the “Company”) of his resignation as Chairperson of the Company’s board of directors (the “Board”), effective June 13, 2023, and his resignation as a director of the Board, effective June 15, 2023.
On October 3, 2022, Robert King, Ph.D., Chief Development Officer of Alector, Inc. (the “Company”), notified the Company of his decision to resign from his position, effective October 28, 2022, to pursue another professional opportunity.
On March 29, 2022, Alector, Inc. (“Alector”) announced the appointment of Gary Romano, Ph.D., M.D., as Alector’s Chief Medical Officer , effective May 23, 2022.
On February 7, 2022, Alector, Inc. (“Alector”) announced the appointment of Marc Grasso, M.D. as Alector’s Chief Financial Officer.
Max materiality 0.90 · Median 0.65 · Most common event earnings